title: M48U1 CD4 mimetic has a sustained inhibitory effect on cell-associated HIV-1 by attenuating virion infectivity through gp120 shedding.
abstract: BACKGROUND
  HIV-1 infected cells can establish new infections by crossing the vaginal epithelia and subsequently producing virus in a milieu that avoids the high microbicide concentrations of the vaginal lumen.
  
  
  RESULTS
  To address this problem, here, we report that pretreatment of HIV-infected peripheral blood mononuclear cells (PBMCs) with a 27 amino acid CD4-mimetic, M48U1, causes dramatic and prolonged reduction of infectious virus output, due to its induction of gp120 shedding.
  
  
  CONCLUSIONS
  M48U1 may, therefore, be valuable for prophylaxis of mucosal HIV-1 transmission.
authors: Department of Biomedical Sciences, Unit of Virology, Institute of Tropical Medicine, Antwerp, B-2000, Belgium.
authors: Philippe
authors: P
authors: Selhorst
authors: Katrijn
authors: K
authors: Grupping
authors: Tommy
authors: T
authors: Tong
authors: Ema T
authors: ET
authors: Crooks
authors: Loïc
authors: L
authors: Martin
authors: Guido
authors: G
authors: Vanham
authors: James M
authors: JM
authors: Binley
authors: Kevin K
authors: KK
authors: Ariën
mesh_terms: D019380:Anti-HIV Agents / Q000378:metabolism*; D032701:Biomimetics; D015704:CD4 Antigens / Q000378:metabolism*; D018562:Disease Transmission, Infectious / Q000517:prevention & control; D005260:Female; D015699:HIV Envelope Protein gp120 / Q000037:antagonists & inhibitors*; D015658:HIV Infections / Q000517:prevention & control / Q000635:transmission; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000821:virology; D009092:Mucous Membrane / Q000821:virology; D014621:Vagina / Q000821:virology; D014771:Virion / Q000187:drug effects*
chemical_list: D019380:Anti-HIV Agents; D015704:CD4 Antigens; D015699:HIV Envelope Protein gp120; C514793:gp120 protein, Human immunodeficiency virus 1
references: AIDS. 2010 Jan 16;24(2):163-87
references: 20010071
references: Antimicrob Agents Chemother. 2012 Feb;56(2):805-15
references: 22083472
references: Sci Transl Med. 2010 Feb 10;2(18):18re1
references: 20371483
references: Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2189-93
references: 2006155
references: PLoS One. 2011;6(8):e22635
references: 21829638
references: J Virol. 2008 Apr;82(8):4154-8
references: 18272571
references: Curr Biol. 1997 Jul 1;7(7):534-7
references: 9210380
references: J Clin Invest. 2002 Jan;109(2):205-11
references: 11805132
references: Antimicrob Agents Chemother. 2008 Mar;52(3):909-14
references: 18086845
references: Antimicrob Agents Chemother. 2002 Jun;46(6):1851-6
references: 12019100
references: J Virol. 2012 Apr;86(7):3574-87
references: 22301141
references: PLoS Pathog. 2012;8(12):e1003071
references: 23236282
references: J Biol Chem. 2011 Jun 17;286(24):21706-16
references: 21487012
references: J Infect Dis. 2010 Aug 15;202(3):337-44
references: 20569157
references: Rev Med Virol. 2011 Mar;21(2):110-33
references: 21412935
references: J Virol. 1997 Apr;71(4):3023-30
references: 9060662
references: Biol Reprod. 1997 Feb;56(2):537-43
references: 9116158
references: AIDS. 2001 Nov 23;15(17):2231-8
references: 11698695
references: Retrovirology. 2012 May 02;9:36
references: 22551420
references: AIDS. 2009 Jan 14;23(2):183-8
references: 19098487
references: Nature. 2010 Mar 11;464(7286):217-23
references: 20220840
references: J Virol. 2010 Apr;84(7):3516-27
references: 20089656
references: Science. 1990 Nov 23;250(4984):1139-42
references: 2251501
references: Nat Biotechnol. 2003 Jan;21(1):71-6
references: 12483221
references: J Exp Med. 2011 Mar 14;208(3):439-54
references: 21357743
references: J Antimicrob Chemother. 2008 Apr;61(4):818-26
references: 18270220